{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:27:41Z","timestamp":1790274461714,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.14283\/jpad.2024.83","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T08:32:38Z","timestamp":1714379558000},"page":"897-902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?"],"prefix":"10.1016","volume":"11","author":[{"given":"Roxanna","family":"Korologou-Linden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kalsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kafetsouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Olawale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wingfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mummery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hayhoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.T.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2024.83_bib1","author":"World Health Organization"},{"issue":"3","key":"10.14283\/jpad.2024.83_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 Alzheimer's disease facts and figures","volume":"16","year":"2020","journal-title":"Alzheimer's and Dementia"},{"issue":"6","key":"10.14283\/jpad.2024.83_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrneurol.2017.63","article-title":"The changing prevalence and incidence of dementia over time - current evidence","volume":"13","author":"Wu","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.14283\/jpad.2024.83_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-016-0188-8","article-title":"Recent global trends in the prevalence and incidence of dementia, and survival with dementia","volume":"8","author":"Prince","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"10.14283\/jpad.2024.83_bib5","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/archneur.1994.00540210060013","article-title":"Clinical-neuropathological correlations in Alzheimer's disease and related dementias","volume":"51","author":"Galasko","year":"1994","journal-title":"Arch Neurol"},{"issue":"1","key":"10.14283\/jpad.2024.83_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00702-021-02449-2","article-title":"Recent update on the heterogeneity of the Alzheimer's disease spectrum","volume":"129","author":"Jellinger","year":"2022","journal-title":"J Neural Transm"},{"issue":"17","key":"10.14283\/jpad.2024.83_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2012.3556","article-title":"Dementia From Alzheimer Disease and Mixed Pathologies in the Oldest Old","volume":"307","author":"James","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"10.14283\/jpad.2024.83_bib8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer's disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimer's and Dementia"},{"issue":"2","key":"10.14283\/jpad.2024.83_bib9","article-title":"Alzheimer's disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"10284","key":"10.14283\/jpad.2024.83_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.14283\/jpad.2024.83_bib11","author":"CenterWatch"},{"key":"10.14283\/jpad.2024.83_bib12","author":"CenterWatch"},{"key":"10.14283\/jpad.2024.83_bib13","series-title":"Alzheimer's disease [Internet]. Vol. 1, Nature Reviews Disease Primers","first-page":"1","author":"Masters","year":"2015"},{"issue":"2","key":"10.14283\/jpad.2024.83_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.14283\/jpad.2024.83_bib15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0141076816671939","article-title":"General practitioner referrals to memory clinics: are referral criteria delaying the diagnosis of dementia?","volume":"109","author":"Hayhoe","year":"2016","journal-title":"J R Soc Med"},{"key":"10.14283\/jpad.2024.83_bib16","series-title":"The Dementia Care Pathway. Full Implementation guidance","author":"Royal College of Psychiatrists","year":"2018"},{"issue":"4","key":"10.14283\/jpad.2024.83_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/jnnp-2017-316844","article-title":"Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis","volume":"89","author":"Rizzo","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.14283\/jpad.2024.83_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimer's & Dementia"},{"issue":"9","key":"10.14283\/jpad.2024.83_bib19","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.56.9.1143","article-title":"Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"56","author":"Knopman","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.14283\/jpad.2024.83_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer's Disease Centers, 2005\u20132010","volume":"71","author":"Beach","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"issue":"7","key":"10.14283\/jpad.2024.83_bib21","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jalz.2018.02.012","article-title":"Accuracy of general hospital dementia diagnoses in England: Sensitivity, specificity, and predictors of diagnostic accuracy 2008\u20132016","volume":"14","author":"Sommerlad","year":"2018","journal-title":"Alzheimer's & Dementia"},{"issue":"6","key":"10.14283\/jpad.2024.83_bib22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZERALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.14283\/jpad.2024.83_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.14283\/jpad.2024.83_bib24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","article-title":"Developing the ATX(N) classification for use across the Alzheimer disease continuum","volume":"17","author":"Hampel","year":"2021","journal-title":"Nature Reviews Neurology"},{"issue":"21","key":"10.14283\/jpad.2024.83_bib25","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/eurheartj\/ehab922","article-title":"Effect of a multi-domain lifestyle intervention on cardiovascular risk in older people: the FINGER trial","volume":"43","author":"Lehtisalo","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.14283\/jpad.2024.83_bib26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","article-title":"Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies","volume":"81","author":"Mattsson-Carlgren","year":"2024","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.14283\/jpad.2024.83_bib27","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3\u201345 Study: Design of a prevention trial for Alzheimer's disease","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimer's & Dementia"},{"key":"10.14283\/jpad.2024.83_bib29","first-page":"29","article-title":"The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint","author":"J\u00f6nsson","year":"2023","journal-title":"The Lancet Regional Health - Europe"},{"key":"10.14283\/jpad.2024.83_bib30","author":"NHS England"},{"key":"10.14283\/jpad.2024.83_bib31","unstructured":"Gauthier S R-NPMJWC. World Alzheimer Report 2021. Journey through the diagnosis of dementia. London, England; 2021. Chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.alzint.org\/u\/World-Alzheimer-Report-2021.pdf. Accessed 23rd January 2024."},{"issue":"2","key":"10.14283\/jpad.2024.83_bib32","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200258","article-title":"The Importance of Apolipoprotein E Genetic Testing in the Era of Amyloid Lowering Therapies","volume":"14","author":"Ronay","year":"2024","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"10.14283\/jpad.2024.83_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy","volume":"9","author":"Barakos","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2024.83_bib34","author":"NICE"},{"issue":"4","key":"10.14283\/jpad.2024.83_bib35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer's and Dementia"},{"issue":"7990","key":"10.14283\/jpad.2024.83_bib36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41586-023-06802-1","article-title":"Organ aging signatures in the plasma proteome track health and disease","volume":"624","author":"Oh","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.14283\/jpad.2024.83_bib37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s43587-023-00565-0","article-title":"Plasma proteomic profiles predict future dementia in healthy adults","volume":"4","author":"Guo","year":"2024","journal-title":"Nature Aging"},{"issue":"3","key":"10.14283\/jpad.2024.83_bib38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.14283\/jpad.2023.69","article-title":"What Is Reasonable and Necessary for Alzheimer Patients from Randomized Clinical Trials to Clinical Practice?","volume":"10","author":"Middleton","year":"2023","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"issue":"4","key":"10.14283\/jpad.2024.83_bib39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.14283\/jpad.2022.85","article-title":"Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU\/US CTAD Task Force","volume":"9","author":"Angioni","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"Suppl 1","key":"10.14283\/jpad.2024.83_bib40","first-page":"S1","article-title":"TRAILBLAZER-ALZ3 trial design and rationale","volume":"8","author":"Tariot","year":"2021","journal-title":"J Prev Alzheimer's Dis"},{"key":"10.14283\/jpad.2024.83_bib41","article-title":"Plasma A\u03b242\/A\u03b240 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease","author":"Rissman","year":"2023","journal-title":"Alzheimer's & Dementia"},{"issue":"18","key":"10.14283\/jpad.2024.83_bib42","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"key":"10.14283\/jpad.2024.83_bib43","first-page":"1","article-title":"Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests","volume":"2024","author":"Barth\u00e9lemy","year":"2024","journal-title":"Nature Medicine"},{"issue":"17","key":"10.14283\/jpad.2024.83_bib44","doi-asserted-by":"crossref","first-page":"E1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.14283\/jpad.2024.83_bib45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/alz.12395","article-title":"Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau","volume":"18","author":"Janelidze","year":"2022","journal-title":"Alzheimer's and Dementia"},{"issue":"2","key":"10.14283\/jpad.2024.83_bib46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","article-title":"Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.14283\/jpad.2024.83_bib47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.14283\/jpad.2021.70","article-title":"Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention","volume":"9","author":"Udeh-Momoh","year":"2022","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"issue":"11","key":"10.14283\/jpad.2024.83_bib48","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-Head Comparison of 8 Plasma Amyloid-\u03b2 42\/40 Assays in Alzheimer Disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"issue":"7691","key":"10.14283\/jpad.2024.83_bib49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"17","key":"10.14283\/jpad.2024.83_bib50","doi-asserted-by":"crossref","first-page":"E1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"issue":"5","key":"10.14283\/jpad.2024.83_bib51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.14283\/jpad.2024.83_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-021-00942-0","article-title":"The accuracy and robustness of plasma biomarker models for amyloid PET positivity","volume":"14","author":"Benedet","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.14283\/jpad.2024.83_bib53","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline","volume":"140","author":"Lantero Rodriguez","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"S5","key":"10.14283\/jpad.2024.83_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/alz.053452","article-title":"Prediction of future Alzheimer's disease dementia using plasma phosphotau combined with other accessible measures","volume":"17","author":"Palmqvist","year":"2021","journal-title":"Alzheimer's & Dementia"},{"issue":"3","key":"10.14283\/jpad.2024.83_bib55","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nature Medicine"},{"issue":"5","key":"10.14283\/jpad.2024.83_bib56","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.14283\/jpad.2024.83_bib57","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.14283\/jpad.2024.83_bib58","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease","volume":"17","author":"Simr\u00e9n","year":"2021","journal-title":"Alzheimer's & Dementia"},{"issue":"8","key":"10.14283\/jpad.2024.83_bib59","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.14283\/jpad.2024.83_bib60","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nature Medicine"},{"issue":"3","key":"10.14283\/jpad.2024.83_bib61","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline","volume":"140","author":"Lantero Rodriguez","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.14283\/jpad.2024.83_bib62","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-022-02408-5","article-title":"Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change","volume":"143","author":"Smirnov","year":"2022","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.14283\/jpad.2024.83_bib63","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217123","article-title":"Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads","volume":"15","author":"Salvad\u00f3","year":"2023","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.14283\/jpad.2024.83_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-022-00578-0","article-title":"Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels","volume":"17","author":"Murray","year":"2022","journal-title":"Mol Neurodegener"},{"issue":"12","key":"10.14283\/jpad.2024.83_bib65","doi-asserted-by":"crossref","first-page":"E1229","DOI":"10.1212\/WNL.0000000000012513","article-title":"Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy","volume":"97","author":"Grothe","year":"2021","journal-title":"Neurology"},{"issue":"12","key":"10.14283\/jpad.2024.83_bib66","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nature Medicine"},{"key":"10.14283\/jpad.2024.83_bib67","first-page":"1","article-title":"Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer's Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project","author":"Malzbender","year":"2024","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"issue":"8","key":"10.14283\/jpad.2024.83_bib68","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s43587-022-00269-x","article-title":"Designing the next-generation clinical care pathway for Alzheimer's disease","volume":"2","author":"Hampel","year":"2022","journal-title":"Nature Aging"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724000141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724000141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:07:37Z","timestamp":1737320857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724000141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2274580724000141"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2024.83","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2024.83","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}